Influenza A
Conditions
Interventions
Oseltamivir Phosphate Group:Oseltamivir phosphate capsules, 1 capsule per dose, 2 times daily, orally
Combined Treatment Group:Modified Yinqiao Decoction + Oseltamivir phosphate capsules, administered as per the above dosage
Control Group:Adequate hydration and sufficient rest
Modified Yinqiao Decoction Group:Modified Yinqiao Decoction, 1 sachet per dose, 2 times daily, orally
Sponsors
The first teaching hospital of Tianjin University of TCM
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: 1.Meets the diagnostic criteria for Influenza A; 2.Meets the diagnostic criteria for Wind-Heat Syndrome of the common cold; 3.Disease duration =48 hours; 4.Age between 18 and 65 years (including 18 and 65 years old); 5.Informed consent process complies with ethical requirements, and the subject has signed the informed consent form.
Exclusion criteria
Exclusion criteria: Exclusion Criteria: 1.Received influenza vaccination within the past 12 months; 2.History of acute sinusitis, otitis media, bronchitis, or pneumonia within the past 12 months, or history of chronic sinusitis or otitis media; 3.Comorbidities involving chronic respiratory, cardiovascular (excluding hypertension), urinary, liver and biliary, hematological, neuromuscular, metabolic, or endocrine systems; 4.Immunosuppressive conditions (including but not limited to those receiving immunosuppressive therapy or HIV infection); Body mass index (BMI) >30; 5.Pregnant, planning to become pregnant, perinatal, or breastfeeding women; 6.Already received antiviral or traditional Chinese medicine treatment for influenza; 7.Suspected or confirmed history of alcohol or substance abuse; 8.Legally defined disabilities (blindness, deafness, muteness, intellectual disability, mental disorders, etc.); 9.Known or suspected allergy to the components of the study medication; 10.Participation in other drug clinical trials within the past 3 months; 11.Considered unsuitable for participation in this clinical trial by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Median time to disease recovery; | — |
Secondary
| Measure | Time frame |
|---|---|
| Daily cumulative disease recovery rate from day 2 to day 5 post-treatment;Median time to fever resolution;TCM syndrome recovery rate;Disappearance rate and median time to disappearance of accompanying symptoms/TCM symptoms (sore throat, aversion to wind-cold, headache, muscle/joint pain, fatigue, cough, nasal congestion, and runny nose);Incidence of complications; | — |
Countries
CHINA
Contacts
Public ContactLiu Min
The first teaching hospital of Tianjin University of TCM
Outcome results
None listed